Headless WordPress - PROD

Narrow manufacturing windows make early identification essential for eligible patients

https://www.sharecare.com/hcp/hematology-oncology/timely-referral-metastatic-melanoma

Timely referral in metastatic melanoma: Why early evaluation for cellular therapy matters

Delivering complex, multi-step therapies requires structured team-based coordination

https://www.sharecare.com/hcp/hematology-oncology/coordinated-care-advanced-melanoma-centers

Coordinated care for advanced melanoma: The role of multidisciplinary treatment centers

Early identification through AI-assisted tools may inform more timely referral pathways

https://www.sharecare.com/hcp/hematology-oncology/ai-melanoma-detection-clinical-judgment

Artificial intelligence (AI) in melanoma detection: Supporting, not replacing, clinical judgment

Featured Content

Dx Dialogues: Metastatic Melanoma

Yana Najjar, MD, Associate Professor of Medicine at UPMC Hillman Cancer Center and Director of the Clinical and Translational Research Center, discusses how systemic therapy for advanced unresectable or metastatic melanoma continues to evolve, when to refer patients for cellular therapy to maximize benefit, and the emerging approaches and remaining gaps shaping the future of care.